(Circulation. 2000;102:1120.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Cardiovascular Research Institute (R.K., M.K.H., S.F.), Washington Hospital Center, Washington, DC; Beth Israel-Deaconess Hospital (D.S.B., R.J.L., D.W., D.J.C., R.E.K.), Boston, Mass; the Cardiovascular Research Foundation, Lenox Hill Hospital (J.W.M., M.B.L.), New York, NY; and Northwestern University Medical Center (R.C.H., R.O.B.), Chicago, Ill.
Correspondence to Ran Kornowski, MD, Cardiovascular Research Foundation, Washington Hospital Center, 110 Irving St NW, 4B-1, Washington, DC 20010. E-mail rxk3{at}mhg.edu
BackgroundDirect myocardial revascularization (DMR) has been examined as an alternative treatment for patients with chronic refractory myocardial ischemic syndromes who are not candidates for conventional coronary revascularization.
Methods and ResultsWe used left ventricular
electromagnetic guidance in 77 patients with chronic refractory angina
(56 men, mean age 61±11 years, ejection fraction 0.48±0.11) to
perform percutaneous DMR with an Ho:YAG laser at 2
J/pulse. Procedural success (laser channels placed in prespecified
target zones) was achieved in 76 of 77 patients with an average of
26±10 channels (range 11 to 50 channels). The rate of major
in-hospital cardiac adverse events was 2.6%, with no deaths or
emergency operations, 1 patient with postprocedural pericardiocentesis,
and 1 patient with minor embolic stroke. The rate of out-of-hospital
adverse cardiac events (up to 6 months) was 2.6%, with 1 patient with
myocardial infarction and 1 patient with stroke. Exercise duration
after DMR increased from 387±179 to 454±166 seconds at 1 month and to
479±161 seconds at 6 months (P=0.0001). The time to
onset of angina increased from 293±167 to 377±176 seconds at 1 month
and to 414±169 seconds at 6 months (P=0.0001).
Importantly, the time to ST-segment depression (
1 mm) also
increased from 327±178 to 400±172 seconds at 1 month and to 436±175
seconds at 6 months (P=0.001). Angina (Canadian
Cardiovascular Society classification) improved from
3.3±0.5 to 2.0±1.2 at 6 months (P<0.001). Nuclear
perfusion imaging studies with a dual-isotope technique, however,
showed no significant improvements at 1 or 6 months.
ConclusionsPercutaneous DMR guided by left ventricular mapping is feasible and safe and reveals improved angina and prolonged exercise duration for up to a 6-month follow-up.
Key Words: myocardium lasers ischemia revascularization angina
This article has been cited by other articles:
![]() |
M. B. Leon, R. Kornowski, W. E. Downey, G. Weisz, D. S. Baim, R. O. Bonow, R. C. Hendel, D. J. Cohen, E. Gervino, R. Laham, et al. A Blinded, Randomized, Placebo-Controlled Trial of Percutaneous Laser Myocardial Revascularization to Improve Angina Symptoms in Patients With Severe Coronary Disease J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1812 - 1819. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Bridges, K. A. Horvath, W. C. Nugent, D. M. Shahian, C. K. Haan, R. J. Shemin, K. B. Allen, and F. H. Edwards The Society of Thoracic Surgeons practice guideline series: transmyocardial laser revascularization Ann. Thorac. Surg., April 1, 2004; 77(4): 1494 - 1502. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ruel, R. A. Kelly, and F. W. Sellke Therapeutic Angiogenesis, Transmyocardial Laser Revascularization, and Cell Therapy Card. Surg. Adult, January 1, 2003; 2(2003): 715 - 750. [Full Text] |
||||
![]() |
R. Kornowski Left ventricular electromechanical mapping for determination of myocardial function and viability J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1075 - 1078. [Full Text] [PDF] |
||||
![]() |
J. Lessick, G. Hayam, A. Zaretsky, S. A. Reisner, Y. Schwartz, and S. A. Ben-Haim Evaluation of inotropic changes in ventricular function by NOGA mapping: comparison with echocardiography J Appl Physiol, August 1, 2002; 93(2): 418 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Stone, P. S. Teirstein, R. Rubenstein, D. Schmidt, P. L. Whitlow, E. J. Kosinski, G. Mishkel, and J. A. Power A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1581 - 1587. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.V Patil, E Nikolsky, M Boulos, E Grenadier, and R Beyar Multivessel coronary artery disease: current revascularization strategies Eur. Heart J., July 2, 2001; 22(14): 1183 - 1197. [PDF] |
||||
![]() |
P. R. Vale, D. W. Losordo, C. E. Milliken, M. C. McDonald, L. M. Gravelin, C. M. Curry, D. D. Esakof, M. Maysky, J. F. Symes, and J. M. Isner Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients With Chronic Myocardial Ischemia Circulation, May 1, 2001; 103(17): 2138 - 2143. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |